Non-Small Cell Lung Cancer Treatment (PDQ®)

Non-small cell lung cancer (NSCLC) treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Get detailed information about newly diagnosed and recurr...

Cancer-associated fibroblast phenotypes are associated with patient outcome in n

in non-small cell lung cancer Lena Cords Stefanie Engler Martina Haberecker Holger Moch... but clinical trials broadly targeting the tumor stroma have so far not succeeded.23 ,24 ,25 ,26...

Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemothe....

Zhao et al. developed a decision tree prediction model (DT10) for immunotherapy efficacy in non-small cell lung cancer by integrating public and real-world data. Incorporating clinical pathology an...

Non-Small Cell Lung Cancer Treatment

Non-small cell lung cancer (NSCLC) treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Laser therapy, photodynamic therapy, cryosurgery, and ele...

Lung Cancer—Patient Version

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. Smoking causes most lung cancers, but nonsmokers can also develop lung cancer. Start here to find inform...

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A....

III non-small-cell lung cancer (NSCLC) comprises a highly heterogeneous group of tumors with different clinical... GEMSTONE-301 trials.19 ,20 ,21 ,22 We postulated that adding immunotherapy...

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtype....

Highlights ; · Small cell lung cancer subtypes can be assessed using RNA-seq and predictive models ; · Small cell lung cancer subtypes have subtype-specific DNA methylation profiles ; · DNA methylation allows subtyping from both tissue and liquid biopsies

Lung Cancer Immunotherapy - Non-Small Cell Lung Cancer Studies

ImmunityBio conducts advanced medical research and runs clinical trials to find new immunotherapies for diseases like lung cancer. Learn more or see if you qualify for our next non-small cell lung...

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small- cell lung cancer: ....

III non-small-cell lung cancer (NSCLC) comprises a highly heterogeneous group of tumors with different clinical manifesta... 1 trials in pretreated advanced solid tumors, 23,24 and...

Early-onset cancers: Biological bases and clinical implications: Cell Reports Medicine

From clinical observation to testable hypotheses · The clinical relevance of EO-cancer rise is highlighted by their emergence as the primary cause of mortality in adolescents and young adults (15–49 years) in world regions with a middle-to-high socio-demographic index, overtaking cardiovascular diseases that predominated in the 1990s.11 Worldwide incidence of EO cancer increased by almost 80% from 1990 to 2019, and the number of EO-cancer deaths increased as well by around 30%.12 Indeed, even if with different trends likely due to local envi ...